Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Posts
- Category: Articles (continued)
- Oral feeding in Huntington’s disease: a guideline document for speech and language therapists
- Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment
- Parkinson's, Huntington's disease research makes advances with stem cells: Discoveries
- PBT2 recommended for orphan designation in Europe
- Penn Biologists Identify a Key Enzyme Involved in Protecting Nerves From Degeneration
- Phosphodiesterase inhibitors: new HD drugs entering trials soon
- Planning a ‘Dancing at the Vatican’ screening to celebrate the global Huntington’s disease community’s journey
- Possible role for Huntington’s gene discovered
- Postdoctoral Fellowship, Huntington's Disease
- Potential new treatments for depression uncovered by research into Huntington's
- Potential Therapeutic Target for Huntington’s Disease
- Potential Treatment for Huntington's Disease, Found Effective, Safe in Mice, Monkeys, Enters Clinical Testing
- Potential treatment for Huntington’s disease discovered by NUIG researchers
- Prana Alzheimer's disease data features at world leading conference
- Prana Announces Successful Phase 2 Results in Huntington Disease Trial
- Prana Biotechnology Investor Presentation and Audio Recording - Phase 2 HD trial
- Prana Completes Phase 2 Huntington Disease Trial with PBT2
- Prana Completes Recruitment in Huntington Trial
- Prana drug treatment PBT2 named one of TopNeuroscience Projects to Watch
- Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial
- Prana presents new benchmark test to assess Huntington’s Disease patients in clinical trials
- Prana Provides Huntington Disease Trial Update
- Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease
- Prana to present at New York Academy of Science Symposium on November 29 th
- Prana Updates Progress on PBT2 Trials in Alzheimer’s and Huntington’sDiseases
- Prana's PBT2 receives FDA Orphan Drug designation for treatment of Huntington diseaseread more
- Prana’s Huntington Disease trial analysis to feature at global movement disorder conference
- Prana’s PBT2 presented at the Huntington’s Disease Society of America National Convention
- Predict the onset and course of Huntington's disease
- Premio Nobel per la Fisiologia o Medicina 2012: un approfondimento
- Pride-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease
- Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United States
- PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
- Production of toxic protein causes common neurodegenerative disorder
- Programme Leader: Professor Giovanna Mallucci MD PhD
- Proposed drug may reverse Huntington's disease symptoms
- Protein aggregates save cells during aging
- Proteomic analysis of wild-type and mutant huntingtin associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis
- PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease
- PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program
- QR Pharma Begins Collaboration on Posiphen and Huntington’s disease
- Quanterix to Host Webinar on Predicting the Progression of Neurodegeneration with a Blood Test
- Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington's disease
- R6/2 Huntington's Disease Mice Develop Early and Progressive Abnormal Brain Metabolism and Seizures
- Rallentare il processo di invecchiamento combatte Alzheimer, Parkinson e Huntington
- Range of brain diseases could be treated by single drug
- Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial
- Raptor Pharmaceutical Completes Enrollment in Phase 2/3 Clinical Trial of RP103 for the Potential Treatment of Huntington's Disease
- Raptor Plans to Advance RP103 in a Registration Study in Huntington's Disease Based on Favorable Treatment Effects at 36 Months in CYST-HD Trial
- Raptor Receives Orphan Drug Designation for Cysteamine Bitartrate in Huntington's Disease From the European Commission
Plugin by dagondesign.com
